Results 51 to 60 of about 14,249 (201)

Kynurenine pathway inhibition reduces central nervous system inflammation in a model of human African trypanosomiasis [PDF]

open access: yes, 2009
Human African trypanosomiasis, or sleeping sickness, is caused by the protozoan parasites <i>Trypanosoma brucei rhodesiense</i> or <i>Trypanosoma brucei gambiense</i>, and is a major cause of systemic and neurological disability ...
Adams   +37 more
core   +2 more sources

Integration of Machine Learning‐QSAR and Polypharmacology in Drug Discovery for Leishmaniasis Using Natural and Repurposed Compounds

open access: yesChemistrySelect, Volume 10, Issue 21, June 4, 2025.
Leishmaniasis affects over 1 billion people worldwide, with current treatments limited by toxicity and efficacy. This study used machine learning (ML), QSAR, and polypharmacology to identify potential drug candidates, analyzing 12,072 compounds with random forest and XGBoost models.
Laís Salvador do Amaral   +7 more
wiley   +1 more source

Nebulized Pentamidine-Induced Acute Renal Allograft Dysfunction

open access: yesCase Reports in Transplantation, 2013
Acute kidney injury (AKI) is a recognised complication of intravenous pentamidine therapy. A direct nephrotoxic effect leading to acute tubular necrosis has been postulated.
Siddhesh Prabhavalkar   +4 more
doaj   +1 more source

Bisbenzamidines as Antifungal Agents. Are Both Amidine Functions Required to Observe an Anti-Pneumocystis carinii Activity?

open access: yesMolecules, 2010
A library of 19 novel 4-(4-phenylpiperazine-1-yl)benzamidines has been synthesized and evaluated in vitro against Pneumocystis carinii. Among these compounds, N-ethyl- and N-hexyl-4-(4-phenylpiperazine-1-yl)benzamidines emerged as the most promising ...
Julien Laurent   +6 more
doaj   +1 more source

Long term outcomes and prognostics of visceral leishmaniasis in HIV infected patients with use of pentamidine as secondary prophylaxis based on CD4 level: a prospective cohort study in Ethiopia. [PDF]

open access: yesPLoS Neglected Tropical Diseases, 2019
BACKGROUND:The long-term treatment outcome of visceral leishmaniasis (VL) patients with HIV co-infection is complicated by a high rate of relapse, especially when the CD4 count is low.
Ermias Diro   +17 more
doaj   +1 more source

First report of treatment failure in a patient with cutaneous leishmaniasis infected by Leishmania (Viannia) naiffi carrying Leishmania RNA virus: a fortuitous combination?

open access: yesRevista da Sociedade Brasileira de Medicina Tropical, 2019
We report the case of a 32-year-old man from Rio de Janeiro, who was infected in the Amazon region of Brazil by Leishmania (Viannia) naiffi. Generally, patients with L.
Ricardo Vieira-Gonçalves   +7 more
doaj   +1 more source

Pneumocystis jirovecii Pneumonia in Cancer Patients, a Lethal Yet Fully Preventable Disease: Insights From a Tertiary Cancer Center in East India

open access: yesAsia-Pacific Journal of Clinical Oncology, Volume 21, Issue 3, Page 319-327, June 2025.
Age and history of lung radiotherapy are overlooked risk factors for Pneumocystis jirovecii pneumonia (PCP) in cancer patients. Prophylaxis appeared to be fully effective. 21‐day mortality rate in the PCP group was 35.4%. Hematologic malignancy and lung cancer patients are at highest risk for mortality.
S. Chatterji   +6 more
wiley   +1 more source

Chimerization at the AQP2–AQP3 locus is the genetic basis of melarsoprol–pentamidine cross-resistance in clinical Trypanosoma brucei gambiense isolates

open access: yesInternational Journal for Parasitology: Drugs and Drug Resistance, 2015
Aquaglyceroporin-2 is a known determinant of melarsoprol–pentamidine cross-resistance in Trypanosoma brucei brucei laboratory strains. Recently, chimerization at the AQP2–AQP3 tandem locus was described from melarsoprol–pentamidine cross-resistant ...
Fabrice E. Graf   +5 more
doaj   +1 more source

Availability and affordability of treatment for Human African Trypanosomiasis. [PDF]

open access: yes, 2001
Human African Trypanosomiasis (HAT) is a re-emerging disease whose usual treatments are becoming less efficient because of the increasing parasite resistance.
Etchegorry, M   +4 more
core   +3 more sources

Pneumocystis jirovecii pneumonia–Immune reconstitution inflammatory syndrome: A review of published cases

open access: yesHIV Medicine, Volume 26, Issue 6, Page 839-848, June 2025.
Abstract Background Immune reconstitution inflammatory syndrome (IRIS) can occur in patients with HIV after commencing antiretroviral therapy. Tuberculosis–IRIS is the most common, and Pneumocystis jirovecii pneumonia (PJP)–IRIS accounts for only 2.7%–4% of IRIS cases.
Natasha Marcella Vaselli   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy